|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC50 |
Gene summary for CCDC50 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC50 | Gene ID | 152137 |
| Gene name | coiled-coil domain containing 50 | |
| Gene Alias | C3orf6 | |
| Cytomap | 3q28 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q8IVM0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 152137 | CCDC50 | S42 | Human | Liver | HCC | 1.60e-02 | 3.11e-01 | -0.0103 |
| 152137 | CCDC50 | S43 | Human | Liver | Cirrhotic | 1.61e-06 | -1.83e-01 | -0.0187 |
| 152137 | CCDC50 | HCC1_Meng | Human | Liver | HCC | 1.45e-73 | 3.44e-01 | 0.0246 |
| 152137 | CCDC50 | HCC2_Meng | Human | Liver | HCC | 3.83e-34 | 1.28e-01 | 0.0107 |
| 152137 | CCDC50 | cirrhotic1 | Human | Liver | Cirrhotic | 8.20e-04 | 4.26e-02 | 0.0202 |
| 152137 | CCDC50 | HCC1 | Human | Liver | HCC | 3.65e-10 | 3.94e+00 | 0.5336 |
| 152137 | CCDC50 | HCC2 | Human | Liver | HCC | 5.94e-19 | 4.72e+00 | 0.5341 |
| 152137 | CCDC50 | Pt13.b | Human | Liver | HCC | 5.37e-15 | 1.83e-01 | 0.0251 |
| 152137 | CCDC50 | Pt13.c | Human | Liver | HCC | 1.59e-02 | -2.74e-01 | 0.0076 |
| 152137 | CCDC50 | Pt14.b | Human | Liver | HCC | 1.79e-03 | 1.47e-01 | 0.018 |
| 152137 | CCDC50 | S014 | Human | Liver | HCC | 1.12e-14 | 1.06e+00 | 0.2254 |
| 152137 | CCDC50 | S015 | Human | Liver | HCC | 2.28e-21 | 1.37e+00 | 0.2375 |
| 152137 | CCDC50 | S016 | Human | Liver | HCC | 2.78e-19 | 1.23e+00 | 0.2243 |
| 152137 | CCDC50 | S027 | Human | Liver | HCC | 6.54e-09 | 1.37e+00 | 0.2446 |
| 152137 | CCDC50 | S028 | Human | Liver | HCC | 2.49e-20 | 1.42e+00 | 0.2503 |
| 152137 | CCDC50 | S029 | Human | Liver | HCC | 5.55e-19 | 1.41e+00 | 0.2581 |
| 152137 | CCDC50 | C04 | Human | Oral cavity | OSCC | 6.04e-14 | 1.11e+00 | 0.2633 |
| 152137 | CCDC50 | C21 | Human | Oral cavity | OSCC | 2.07e-27 | 1.07e+00 | 0.2678 |
| 152137 | CCDC50 | C30 | Human | Oral cavity | OSCC | 7.19e-46 | 2.28e+00 | 0.3055 |
| 152137 | CCDC50 | C38 | Human | Oral cavity | OSCC | 7.93e-21 | 2.01e+00 | 0.172 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC50 | SNV | Missense_Mutation | novel | c.778N>A | p.His260Asn | p.H260N | Q8IVM0 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC50 | SNV | Missense_Mutation | c.431N>G | p.Tyr144Cys | p.Y144C | Q8IVM0 | protein_coding | tolerated(0.05) | benign(0.018) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC50 | SNV | Missense_Mutation | novel | c.605N>A | p.Arg202Lys | p.R202K | Q8IVM0 | protein_coding | tolerated(0.62) | benign(0) | TCGA-BH-A6R8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC50 | SNV | Missense_Mutation | c.843A>T | p.Gln281His | p.Q281H | Q8IVM0 | protein_coding | tolerated(0.31) | possibly_damaging(0.471) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CCDC50 | SNV | Missense_Mutation | rs761262340 | c.1042N>A | p.Glu348Lys | p.E348K | Q8IVM0 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| CCDC50 | SNV | Missense_Mutation | c.23A>T | p.Gln8Leu | p.Q8L | Q8IVM0 | protein_coding | deleterious(0.02) | benign(0.279) | TCGA-E9-A24A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CCDC50 | insertion | In_Frame_Ins | novel | c.779_780insTGT | p.His260_Gln261insVal | p.H260_Q261insV | Q8IVM0 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CCDC50 | insertion | Frame_Shift_Ins | novel | c.749_750insATATGAGCATCCAGCTTGTTTCTGCATAG | p.Cys251TyrfsTer87 | p.C251Yfs*87 | Q8IVM0 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| CCDC50 | insertion | Frame_Shift_Ins | novel | c.1067_1068insA | p.Leu358ThrfsTer22 | p.L358Tfs*22 | Q8IVM0 | protein_coding | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| CCDC50 | SNV | Missense_Mutation | novel | c.576A>C | p.Glu192Asp | p.E192D | Q8IVM0 | protein_coding | tolerated(0.24) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |